Announced Wed, 12 Aug · 17:37 IST
Q1 FY27 Results: Net Loss Narrows to Rs 7.55 Cr vs Rs 13.73 Cr YoY
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.3%1-day move
₹27.11
prior close
₹27.13
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2-1.2-1.0-0.8+3.3+2.4+3.2-0.4-0.9+12.3+13.5+23.0——
Up moveDown movePending
AI summary
Mangalam Drugs posted Q1 FY27 results for quarter ended June 30, 2026. Revenue from operations was nearly flat at Rs 57.12 crore versus Rs 57.21 crore in Q1 FY26. Standalone net loss narrowed sharply to Rs 7.55 crore from Rs 13.73 crore. Consolidated net loss was Rs 7.64 crore. Auditor issued an unmodified limited review opinion. Board appointed new statutory and secretarial auditors for five-year terms.
Likely market impact
Losses shrank sharply year-on-year with steady revenue, but the company remains loss-making. Pending merger awaiting NCLT approval.